Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXGN AxoGen	$15.56 +1.3%	$12.03	$9.22 ▼ $21.00	$715.92M	1	795,708 shs	662,465 shs
LUNG Pulmonx	$1.51 -1.3%	$2.53	$1.47 ▼ $9.37	$61.53M	0.43	446,201 shs	579,516 shs
NPCE NeuroPace	$8.66 +5.0%	$9.72	$5.45 ▼ $18.98	$286.52M	1.89	276,422 shs	434,214 shs
OM Outset Medical	$13.34 -0.1%	$17.68	$5.85 ▼ $25.35	$237.00M	2.14	226,674 shs	124,332 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXGN AxoGen	-0.84%	+8.47%	+36.17%	+34.74%	+25.29%
LUNG Pulmonx	-4.38%	-3.77%	-51.43%	-51.27%	-77.30%
NPCE NeuroPace	-2.02%	-9.64%	-8.94%	-54.50%	+16.20%
OM Outset Medical	-2.34%	+5.37%	-23.36%	-28.23%	+43.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXGN AxoGen	3.0667 of 5 stars	3.5	2.0	3.7	2.5	0.6
LUNG Pulmonx	3.9007 of 5 stars	4.3	4.0	1.1	3.3	1.3
NPCE NeuroPace	3.2801 of 5 stars	3.4	3.0	3.0	3.3	0.6
OM Outset Medical	1.5059 of 5 stars	3.5	2.0	1.9	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXGN AxoGen	3.00	Buy	$26.00	67.10% Upside
LUNG Pulmonx	2.56	Moderate Buy	$7.66	407.57% Upside
NPCE NeuroPace	2.83	Moderate Buy	$16.60	91.66% Upside
OM Outset Medical	3.00	Buy	$24.67	84.91% Upside

Current Analyst Ratings Breakdown

Latest LUNG, AXGN, NPCE, and OM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	OM Outset Medical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$22.00
8/13/2025	NPCE NeuroPace	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/13/2025	NPCE NeuroPace	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$17.00 ➝ $15.00
8/7/2025	OM Outset Medical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $22.00
8/1/2025	LUNG Pulmonx	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.00 ➝ $3.00
7/31/2025	LUNG Pulmonx	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $8.00
7/31/2025	LUNG Pulmonx	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $5.00
7/31/2025	LUNG Pulmonx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $16.00
7/31/2025	LUNG Pulmonx	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$9.00 ➝ $2.50
7/14/2025	OM Outset Medical	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$37.00
5/28/2025	NPCE NeuroPace	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXGN AxoGen	$187.34M	3.82	N/A	N/A	$2.44 per share	6.38
LUNG Pulmonx	$90.55M	0.68	N/A	N/A	$1.70 per share	0.89
NPCE NeuroPace	$88.57M	3.23	N/A	N/A	$0.59 per share	14.68
OM Outset Medical	$119.30M	1.99	N/A	N/A	$8.50 per share	1.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXGN AxoGen	-$9.96M	-$0.10	N/A	N/A	N/A	-2.29%	-4.43%	-2.34%	11/6/2025 (Estimated)
LUNG Pulmonx	-$56.39M	-$1.43	N/A	N/A	N/A	-62.88%	-69.76%	-36.26%	10/29/2025 (Estimated)
NPCE NeuroPace	-$27.14M	-$0.84	N/A	N/A	N/A	-29.29%	-168.61%	-25.48%	N/A
OM Outset Medical	-$127.98M	-$20.29	N/A	∞	N/A	-82.06%	-97.17%	-32.84%	11/5/2025 (Estimated)

Latest LUNG, AXGN, NPCE, and OM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	NPCE NeuroPace	-$0.24	-$0.26	-$0.02	-$0.26	$23.08 million	$23.52 million
7/30/2025	Q2 2025	LUNG Pulmonx	-$0.40	-$0.38	+$0.02	-$0.38	$23.46 million	$23.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXGN AxoGen	N/A	N/A	N/A	N/A	N/A
LUNG Pulmonx	N/A	N/A	N/A	N/A	N/A
NPCE NeuroPace	N/A	N/A	N/A	N/A	N/A
OM Outset Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXGN AxoGen	0.59	4.14	2.67
LUNG Pulmonx	0.54	5.35	4.63
NPCE NeuroPace	3.02	5.47	4.51
OM Outset Medical	0.63	7.47	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXGN AxoGen	80.29%
LUNG Pulmonx	91.04%
NPCE NeuroPace	78.83%
OM Outset Medical	N/A

Insider Ownership

Company	Insider Ownership
AXGN AxoGen	2.78%
LUNG Pulmonx	6.80%
NPCE NeuroPace	20.50%
OM Outset Medical	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXGN AxoGen	450	46.01 million	44.73 million	Optionable
LUNG Pulmonx	250	40.75 million	37.98 million	Optionable
NPCE NeuroPace	170	33.08 million	26.30 million	Optionable
OM Outset Medical	520	17.77 million	17.34 million	Not Optionable

LUNG, AXGN, NPCE, and OM Headlines

Recent News About These Companies

Outset Medical to Present at the 23rd Annual Morgan Stanley Global Healthcare Conference

1 hour ago | globenewswire.com

Outset Medical, Inc. $OM Shares Sold by National Bank of Canada FI

August 19 at 4:15 AM | marketbeat.com

Outset Medical’s Earnings Call Highlights Strong Growth

August 15, 2025 | theglobeandmail.com

Outset Medical (OM) Receives a Hold from Oppenheimer

August 15, 2025 | theglobeandmail.com

Outset Medical Inc.

August 15, 2025 | barrons.com

After Plunging 26.8% in 4 Weeks, Here's Why the Trend Might Reverse for Outset Medical (OM)

August 15, 2025 | zacks.com

Outset Medical (NASDAQ:OM) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

August 8, 2025 | marketbeat.com

What To Expect From Outset Medical Inc (OM) Q2 2025 Earnings

August 7, 2025 | finance.yahoo.com

Outset Medical Reports Strong Q2 Growth and Raises Guidance

August 7, 2025 | msn.com

Outset Medical, Inc. (OM) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

Outset Medical, Inc. (OM) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2025 | zacks.com

Outset Medical Second-Quarter Results Demonstrate Continued Momentum, Punctuated by Strong Revenue Growth, Console Placements and Utilization

August 6, 2025 | globenewswire.com

Uncovering Potential: Outset Medical's Earnings Preview

August 5, 2025 | benzinga.com

TD Asset Management Inc Acquires New Stake in Outset Medical, Inc. (NASDAQ:OM)

August 5, 2025 | marketbeat.com

Outset Medical Appoints Brittni McGill as Chief Nursing Officer to Enhance Dialysis Care Innovation

July 30, 2025 | quiverquant.comQ

Outset Medical Names First Chief Nursing Officer

July 30, 2025 | globenewswire.com

Outset Medical (OM) Projected to Post Earnings on Wednesday

July 30, 2025 | marketbeat.com

840,248 Shares in Outset Medical, Inc. (NASDAQ:OM) Acquired by Massachusetts Financial Services Co. MA

July 20, 2025 | marketbeat.com

Outset Medical to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

July 16, 2025 | globenewswire.com

Why Outset Medical's Rock-Bottom Valuation Masks Explosive Growth

July 7, 2025 | seekingalpha.com

Strength Seen in Outset Medical (OM): Can Its 15.0% Jump Turn into More Strength?

June 25, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LUNG, AXGN, NPCE, and OM Company Descriptions

AxoGen NASDAQ:AXGN

$15.56 +0.20 (+1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$15.78 +0.22 (+1.38%)

As of 04:16 PM Eastern

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Pulmonx NASDAQ:LUNG

$1.51 -0.02 (-1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$1.51 0.00 (0.00%)

As of 04:10 PM Eastern

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

NeuroPace NASDAQ:NPCE

$8.66 +0.41 (+4.98%)

Closing price 03:59 PM Eastern

Extended Trading

$8.65 -0.01 (-0.07%)

As of 04:10 PM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Outset Medical NASDAQ:OM

$13.34 -0.01 (-0.07%)

Closing price 04:00 PM Eastern

Extended Trading

$13.34 0.00 (-0.04%)

As of 04:10 PM Eastern

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time